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Abstract
We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent 
autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival 
(PFS) of older patients was non-inferior to that of younger patients after ASCT. Our null 
hypothesis was that the PFS hazard ratio (HR) for a 5-year increase in age was ≥1.05; the 
alternative (non-inferiority) hypothesis was that the HR was ≤1. The observed HR was 0.94 (95% 
confidence interval [CI] 0.86–1.03); since the CI upper bound was <1.05, we reject the null 
hypothesis and conclude that PFS in older patients was at least as good as in younger patients. We 
cannot reject an analogous null hypothesis for overall survival (HR 1.06 [95% CI 0.94–1.19]), 
since the CI upper bound >1.05. Toxicity was similar across ages and transplant-related mortality 
was minimal. 28% of subjects <65 versus 45% of those ≥65 received maintenance therapy. In 
summary, ASCT prolongs PFS equally well in older vs. younger adults. Although we cannot 
exclude maintenance as a confounder, these data support ASCT for fit seniors with MM.
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Mutiple myeloma (MM) is an incurable cancer of plasma cells with an incidence that rises 
with age and a median age of diagnosis of 66.1 Treatment for MM often includes high-dose 
chemotherapy, usually melphalan, followed by autologous stem cell transplantation (ASCT) 
– an approach that in both decades old and more recent studies has demonstrated the 
capacity to delay relapse and prolong overall survival.2–4 Although ASCT was often not 
offered to senior MM subjects in the past on the basis of age alone, in more recent years the 
growing recognition that physiological age should supersede chronological age as a 
selection criterion for ASCT has resulted in increasing implementation of ASCT in seniors.5 
Multiple studies, including a large one by the Center for International Blood and Marrow 
Transplant Research (CIBMTR), have shown that ASCT in appropriately selected seniors is 
both safe and efficacious, and may also partially be responsible for improvements in survival 
in seniors with MM.6–9 In the current study, our objective was to examine our own 
institutional experience with ASCT in seniors as compared with younger subjects with 
newly diagnosed MM, primarily focusing on ASCT’s ability to delay MM relapse, measured 
as progression-free survival (PFS), but also looking at overall survival (OS) and toxicity.
2 | MATERIALS AND METHODS
We conducted a retrospective study by interrogating our database that tracks all subjects who 
undergo hematopoietic stem cell transplantation at our institution. Subjects were included if 
they underwent first ASCT between December 2000 and April 2013, and within two years 
of the initial MM diagnosis, and if conditioning was only with high-dose melphalan. 
Subjects were excluded if they were participating in other, not yet reported prospective 
therapy studies (i.e., embargoed data) at the time that study data were collected, if they had a 
separate, concurrent malignancy, or if they underwent tandem ASCT or allogeneic stem cell 
transplant. The study was approved by the Institutional Review Board.
Our institution reports data for all subjects undergoing stem cell transplant to CIBMTR, 
including these subjects. Our subjects hence represent in part a subgroup of those described 
in the manuscript reporting CIBMTR’s experience,6 but PFS and OS data were updated by 
review of the electronic health record specifically for this study. Missing OS data in the 
health record were determined by querying the Social Security Death Index.
Induction regimens, ASCT candidacy, stem cell mobilization regimens, melphalan dose and 
post-ASCT maintenance strategies were decided upon according to discretion of the treating 
physician. Subjects were generally mobilized and collected after receiving G-CSF 
(granulocyte colony stimulating factor; filgrastim), cyclophosphamide, and/or plerixafor. 
ASCT for MM is usually performed on an outpatient basis at our institution. On day −1, 
subjects received intravenous high-dose melphalan. Subjects over age 70 or younger subjects 
with impaired renal function (defined as a calculated creatinine clearance of <50 ml/min) 
were usually conditioned with dose-reduced melphalan at 140 mg/m2, whereas other 
subjects generally received the standard 200 mg/m2. On day 0, a minimum of 2 × 106 
CD34+ cells/kg were reinfused. Subjects received G-CSF with supportive care until 
engraftment.
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The number of lines of induction therapy each subject received and determination of 
whether subject received maintenance were tabulated according to published 
recommendations.10 High-risk MM was defined as the presence of any clones containing 
del(17p), t(4;14), 1q gain, del(1p), t(14;16) or t(14;20) by conventional cytogenetics or 
fluorescence in situ hybridization (FISH) data from any bone marrow aspirate performed 
prior to ASCT. All other genetic findings were considered to be standard risk. International 
staging system (ISS)11 stage was determined using results obtained as close to time of 
diagnosis and pre-induction whenever possible. For subjects who were induced elsewhere 
and did not have ISS assessed prior to first evaluation at our institution, we used values 
obtained at their first visit with us.
Response to therapy was evaluated objectively using standard International Myeloma 
Working Group criteria.12 Engraftment after ASCT was defined as transfusion-independent 
platelet levels ≥20,000/uL, and G-CSF-independent white blood cell count ≥1000/uL, each 
for at least three consecutive days. ASCT-related toxicity analyses focused on those that 
could be precisely determined in a retrospective chart review: unexpected hospitalization, 
febrile neutropenia, pneumonitis, and transplant-related mortality (TRM), defined as death 
not related to MM relapse within six months of ASCT.
2.1 | Statistical Considerations
The primary objective of the study was to estimate the association of age in years with PFS; 
secondarily, the association of age with OS was also estimated. PFS and OS were calculated 
from day of stem cell reinfusion. PFS was defined as time to MM progression or death, 
whichever came first. OS was defined as death due to any cause. Given that our primary 
hypothesis was that the PFS and OS of older patients receiving ASCT were similar to that of 
younger patients, the age effect on PFS and OS was tested under non-inferiority hypotheses. 
Specifically, for both PFS and OS the null hypothesis was that the HR for a 5-year increase 
in age was ≥ 1.05, and the alternative hypothesis was that the HR was ≤ 1. The value 1.05 is 
called the “non-inferiority margin” (NIM). The larger the observed HR, the larger the hazard 
of older patients as compared to the hazard of younger patients. While there is almost always 
some subjectivity in choosing a NIM, we chose a conservative NIM of 1.05 because most 
statisticians would consider a HR of 1.05 quite small.
The proportional hazards model was used to estimate the covariate-adjusted HR’s for the 
effect of age on PFS and OS. Backwards selection with a significance-level-to-stay of 0.20 
was used to determine which of the candidate covariates listed in Table 1 to include in the 
final models, with the exception that age and year of transplant were forced into the model. 
The estimated hazard ratios for a 5-year increase in age are presented with 95% confidence 
intervals (CI). If the upper bound of the 95% CI did not include the NIM, the null hypothesis 
was rejected. Kaplan-Meier graphs of PFS and OS by age group (< 65 and ≥ 65) are 
presented for descriptive purposes. The distribution of time to engraftment, post-ASCT 
response status by consensus criteria,12 neutropenia, pneumonitis, and unexpected 
hospitalization were estimated by age group.
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In an initial database search we identified 816 subjects and of those, 435 met the more 
rigorous eligibility criteria for inclusion: 11 subjects were excluded for having plasma cell 
cancers other than MM (e.g., light chain amyloidosis) or a concurrent malignancy separate 
from MM, 45 underwent allogeneic transplant or tandem ASCT, 21 were in the midst of 
ongoing prospective studies with embargoed data, 198 were conditioned with regimens other 
than melphalan monotherapy, and 106 subjects were undergoing their second or higher 
ASCT, or they were >2 years out from their initial MM diagnosis at the time of first ASCT. 
Given the critical prognostic importance of bone marrow FISH and cytogenetic results to the 
study’s primary endpoint of PFS, we excluded another 95 subjects missing those data, 
resulting in 340 subjects available for the analysis. Finally, 17 patients were excluded due to 
missing values on other covariates.
The distribution of baseline and other relevant variables are presented in Table 1. For 
descriptive purposes only, age is dichotomized at age 65 (age in years was used as a 
continuous variable in the PFS and OS models). Most baseline and pre-ASCT characteristics 
were similar, including ISS stage, presence of high-risk genetics, number of induction 
regimens, and whether subjects received thalidomide, lenalidomide or bortezomib as part of 
their pre-ASCT induction therapy. The proportion of those subjects with high-risk genetics 
seems low, but one must consider that many of these subjects were diagnosed prior to the 
routine employment of FISH, and more recently CD138-enriched FISH, which has 
augmented the detection rate of high-risk genetic abnormalities.13 A higher proportion of 
younger subjects underwent cyclophosphamide-based stem cell mobilization and full-dose 
(200 mg/m2) melphalan conditioning.
The distribution of ASCT response status as measured at day +100 post-ASCT is shown in 
Table 2. Overall response rates (i.e., achievement of PR or better) of 0.91 vs. 0.87 were 
observed in younger vs. senior subjects; the rates of VGPR or better were 0.58 vs. 0.65 
(difference of 0.07, 95% CI, −0.05 – 0.18); the CR/sCR rates were 0.10 vs. 0.07 (difference 
of −0.03, 95% CI −0.13 – 0.03) (Table 2).
In the proportional hazards model of PFS, the observed HR for a 5-year increase in age was 
0.94 (95% CI 0.86–1.03). Since the upper bound of the 95% CI did not include the NIM of 
1.05, we concluded that the PFS of older patients was at least as good as that of younger 
patients. In the final PFS model, hemoglobin, cyclophosphamide-based mobilization, and 
pre-ASCT response independently predicted longer PFS (Table 3). Figures 1A and 2A show 
the distribution of PFS by age and genetic risk, respectively.
In the model of OS, the observed HR for a 5-year increase in age was 1.06 (95% CI of 0.94–
1.19). Since the upper bound of 95% CI includes the NIM of 1.05, we conclude that there is 
no statistical evidence in this dataset that the OS of older patients was at least as good as that 
of younger patients. (This conclusion does not imply that the OS of older patients was 
significantly worse than that of younger patients. In fact, a superiority test of the association 
of age with OS had a p-value of 0.34.) Covariates that were retained in the OS model after 
backwards elimination were pre-ASCT hemoglobin, high-risk genetics, and pre-ASCT 
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response (Table 4). Figures 1B and 2B show the distribution of OS by age and genetic risk 
purely for descriptive purposes, respectively.
Median time to white blood cell engraftment was similar post-ASCT, occurring at a 12 days 
in subjects <65 vs. 13 days in subjects ≥65. Platelet engraftment was also similar, at a 
median of 13 and 14 days post-ASCT, respectively.
Toxicity, measured as the incidence of specific events, was similar between groups. Febrile 
neutropenia occurred in 62% and 60%, pneumonitis in 5% vs 9%, and unexpected 
hospitalization (a global measure of toxicity in our primarily outpatient ASCT population) in 
29% and 32% of senior vs younger subjects respectively. TRM was infrequent in both 
groups (Table 2), and in fact, no TRM occurred in subjects above 65. Beyond that, we 
observed no difference in incidence of any of the toxic events analyzed between subjects 
who received full-vs. reduced-dose melphalan (data not shown).
Senior subjects more often received post-ASCT maintenance, usually lenalidomide: 28% of 
younger vs. 43% of older (difference of 0.15, 95% CI, 0.04 – 0.26) (Table 1).
4 | DISCUSSION
ASCT was one of the first therapies shown to prolong survival in MM,2 and despite a 
multitude of new agents that have arrived since the advent of ASCT, most experts agree that 
ASCT remains a standard of care for fit subjects.14,15 Senior adults, who were historically 
denied ASCT due to age alone, now undergo it far more often, supported by publications 
from several groups such as CIBMTR and others6–9 that demonstrate that ASCT is safe and 
effective in select seniors. We now present our own data that support that contention.
In this large retrospective study we detail several key findings as relate to seniors as 
compared to younger MM patients: 1) ASCT is safe; 2) the PFS of seniors is as good as the 
PFS of younger patients; 3) this study provides no statistical evidence that would allow us to 
firmly state that the OS of older patients is as good as the OS of younger patients post-
ASCT.
In terms of point #1, a key principle underlying our findings is the importance of appropriate 
subject selection and empiric modification of ASCT procedures for maximizing the safety of 
ASCT in seniors. We anecdotally state that our group only offers ASCT to seniors if they are 
fit and have limited comorbidities, although in our study we did not have data on such 
considerations beyond those detected on standard pre-ASCT testing. (As an example, we 
had data on renal function because serum creatinine is routinely checked, but no data on the 
presence of coronary artery disease.) In terms of modification of ASCT, our group like many 
others typically dose-reduces melphalan for patients >70. The similar rate of toxicity seen 
across ages and doses of melphalan in this study provides indirect evidence supporting the 
beneficial effect of these practices on patient safety. One also notes that 11% of younger 
subjects received dose-reduced melphalan, primarily due to renal insufficiency (data not 
shown).
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As for points #2 and 3, PFS was as good in senior as compared to younger subjects, whereas 
we have no evidence to state the same for OS. PFS is a composite endpoint that includes 
both MM progression and death and OS includes only death as an event, so our findings 
suggest that ASCT delays progression in younger and older MM patients alike. Conversely, 
this study does not allow us to conclude that ASCT delays death equally across age groups. 
It does not automatically follow that post-ASCT OS is indeed worse in older adults (which 
would require a separate, statistical analysis for superiority), but it stands to reason that if 
OS is truly worse post-ASCT in seniors but time to MM progression is not, then the excess 
of deaths in seniors may be driven by factors unrelated to MM. Simply put, one’s life 
expectancy becomes shorter as one ages due to rising likelihood of death from age-related 
causes, such as heart disease or other cancers.
An important confounder of PFS in our study is the fact that 15% more senior than younger 
subjects received maintenance. The most likely explanation for that finding is that the 
frequency of seniors undergoing ASCT rose with time (Table 1), as did the employment of 
maintenance for all MM patients. Since more seniors underwent ASCT later in the time 
period studied, a greater overall percentage of seniors received maintenance. Maintenance 
unequivocally prolongs PFS by delaying MM progression and so the potential effect of 
maintenance as a confounder is real.16–18 Reassuringly, the similar ORR and depth of 
responses achieved both pre-ASCT and at day +100 post-ASCT, pre-maintenance, in the two 
age groups suggest that the benefits of ASCT are age-independent (i.e., ASCT had a 
similarly beneficial effect on response in both groups). That said, we ideally would have 
included maintenance as a time-dependent covariate in our analyses, but adequately reliable 
data on timing of maintenance treatments in this retrospective study were unavailable and so 
that analysis was not possible. We would note the fact that established predictors of outcome 
in MM, such as depth of response and hemoglobin, were also prognostic in this study, 
adding to the overall validity of our findings. Beyond that, it is somewhat surprising that 
cyclophosphamide-based mobilization predicted longer PFS but high-risk FISH/cytogenetics 
did not, whereas the converse was true for OS. Ultimately that variability probably stems 
from random variation in this retrospective study and/or unknown confounders that were not 
accounted for in multivariate modeling. The genetic analyses were also potentially 
confounded by the fact that FISH panels are now relatively standardized, but those assays 
were only evolving as routine clinical tools during much of the time frame covered by this 
study; it is likely that genetic abnormalities were missed in some patients.
Further limitations not yet mentioned include the fact that this is a retrospective analysis of a 
prospectively maintained database. Subjects were treated with a variety of induction 
regimens and decisions surround ASCT such as candidacy and melphalan dosing were 
discretionary. We attempted to circumvent that heterogeneity by controlling for relevant 
covariates. Another concern with all retrospective studies is that data capture is imperfect. 
Many subjects come to our institution for ASCT after starting induction with community 
physicians, and obtaining rigorous clinical data from outside practices can be challenging 
despite efforts to obtain outside docume. Next, the study covers more than a decade of time 
during which MM treatment and supportive care algorithms evolved substantially, which 
could also affect ASCT outcomes. We addressed that issue by controlling for year of 
treatment in the multivariate analysis. Lastly, we lack information on cause of death in the 
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majority of cases. This would be especially relevant in senior subjects, for whom competing 
risks of death are a very real confounder of OS. Similarly good PFS in senior vs. younger 
subjects post-ASCT shows that ASCT delays relapse independent of age, but ultimately 
showing equivalence in time to MM-related death would further support our overarching 
hypothesis that ASCT delays both MM relapse and MM-related death, independent of age.
Our findings parallel data from other groups:6–9 most importantly, the PFS we observed of 
approximately two years is similar across all these studies, including the largest series by 
Sharma et al..6 While mentioning those other studies we should highlight the uniqueness of 
this one: it is one of the largest single institution studies of this type and included both 
younger and older subjects, which enabled multivariate analysis in which age was 
investigated while controlling for other key covariates. This is of vital importance because 
multiple aspects of MM management that impact prognosis are inextricably linked to age, 
such as choice of induction regimen, melphalan dose, and even decisions regarding ASCT 
candidacy overall. Our study is also one of the most recent ones, going as far forward as 
2013, whereas most other studies stopped with patients transplanted in 2011 or earlier. In the 
current age of rapid evolution in MM therapy, a few years can result in a sizable difference. 
For all these reasons, we believe our unique study adds important data to the literature in 
confirming the earlier findings from those older publications.
Now that we clinicians are moving beyond advanced chronological age as an absolute 
contraindication to ASCT, it remains to be determined how we can optimally select ASCT 
candidates among seniors. Several clinically relevant geriatric assessment instruments have 
been shown to variably predict survival and chemotherapy toxicity in the non-ASCT setting 
in MM19 and in solid tumors.20,21 Such tools could be useful in some day helping to match 
seniors with ideal levels of therapeutic intensity, including ASCT when appropriate, with the 
aim of maximizing likelihood of MM control while ensuring an acceptably low likelihood of 
severe toxicity. Such geriatric assessment studies are being conducted by our group and 
others. Very preliminary pilot studies have been completed that support feasibility,22 but no 
definitive outcomes data are yet available.
Perhaps the broader, most thought-provoking question is not whether ASCT should be 
employed specifically in seniors with MM, but whether ASCT itself is becoming obsolete 
with the advent of so many new drugs including several in the United States late in 2015. 
Some MM experts contend that ASCT is no longer necessary. We disagree. Although it is 
possible that in the future ASCT may fall by the wayside, even the most recent randomized 
studies, which employed novel agents, still support a clear benefit for both PFS and in some 
studies OS when ASCT is employed as part of subjects’ initial MM therapy.3,4 We believe 
that ASCT remains a relevant standard of care for fit older and younger patients alike, until 
data may emerge which demonstrate that it is truly time to retire it.
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FIGURE 1. A, Progression-free survival by age. B, Overall survival by age. A and B. PFS and OS 
by age (figs. 1A and B respectively)
Age was statistically tested as a continuous variable, which cannot be depicted in Kaplan-
Meier curves. Graphs are hence provided for illustrative purposes only
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FIGURE 2. A, Progression-free survival by age, subdivided by genetic risk. B, Overall survival 
by age, subdivided by genetic risk. A and B. PFS and OS by age, subdivided by genetic risk
Age was statistically tested as a continuous variable, which cannot be depicted in Kaplan-
Meier curves. Graphs are hence provided for illustrative purposes only
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TABLE 1
Subject and disease characteristics
Age at Transplant
< 65 years ≥ 65 years Total
Characteristic n=243 (71%) n=97 (29%) N
Median age at ASCT, (IQR) 57 (52 – 61) 68 (66 – 70) 60 (55 – 66)
Gender
  Female 109 (45%) 36 (37%) 145
  Male 134 (55%) 61 (63%) 195
Immunoglobulin subtype
  IgG 142 (58%) 50 (52%) 192
  IgA 50 (21%) 16 (16%) 66
  IgD 1 (<1%) 1 (1%) 2
  IgM 1 (<1%) 1 (1%) 2
  Biclonal 0 (0%) 1 (1%) 1
  Light chain 43 (18%) 26 (27%) 69
  Non-secretory / unknown 6 (2%) 2 (2%) 8
FISH/cytogenetic risk
  Standard 222 (91%) 85 (88%) 307
  High 21 (9%) 12 (12%) 33
ISS stage pre-ASCT
  I 146 (60%) 59 (61%) 205
  II 53 (22%) 21 (22%) 74
  III 30 (12%) 11 (11%) 41
  Unknown / missing 14 (6%) 6 (6%) 20
Number of pre-ASCT induction regimens
  1 177 (73%) 64 (66%) 241
  >1 66 (27%) 33 (34%) 99
Received thalidomide or lenalidomide pre-ASCT 141 (58%) 62 (64%) 203
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Age at Transplant
< 65 years ≥ 65 years Total
Characteristic n=243 (71%) n=97 (29%) N
Received bortezomib pre-ASCT 144 (59%) 65 (67%) 209
Median serum creatinine pre-ASCT (mg/dL), (IQR) 0.9 (0.8 – 1.2) 1.0 (0.8 – 1.2) 0.9 (0.8 – 1.2)
Median hemoglobin pre-ASCT (g/dL), (IQR) 12.1 (10.7 – 13.4) 12.0 (11.0 – 12.9) 12.1 (10.9 – 13.3)
Pre-ASCT response
  CR 28 (12%) 14 (14%) 42
  sCR 4 (2%) 1 (3%) 5
  VGPR 79 (33%) 24 (25%) 103
  PR 108 (44%) 43 (44%) 151
  SD 10 (4%) 5 (5%) 15
  PD 3 (1%) 4 (4%) 7
  Non-secretory/unknown 11 (5%) 6 (6%) 17
Stem cell mobilization / collection regimen
  Filgrastim only 80 (33%) 32 (33%) 112
  Cyclophosphamide 132 (54%) 38 (39%) 170
  Plerixafor 20 (8%) 18 (19%) 38
  Cyclophosphamide + plerixafor 9 (4%) 9 (9%) 18
  Marrow 1 (<1%) 0 (0%) 1
  Unknown 1 (<1%) 0 (0%) 1
Melphalan dose (mg/m2)
  <200 26 (11%) 42 (43%) 68
  200 217 (89%) 55 (57%) 272
Year of transplant
  2000–2004 31 (13%) 8 (8%) 42
  2005–2009 129 (53%) 26 (27%) 155
  2010–2013 83 (33%) 63 (65%) 146
Post-ASCT maintenance
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Age at Transplant
< 65 years ≥ 65 years Total
Characteristic n=243 (71%) n=97 (29%) N
  Lenalidomide orthalidomide alone 56 (23%) 34 (35%) 90
  Bortezomib alone 8 (3%) 4 (4%) 12
  Other regimen 5 (2%) 4 (4%) 9
  Any maintenance 69 (28%) 42 (43%) 111
  No maintenance 174 (72%) 55 (57%) 229
IQR = interquartile range
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TABLE 2
Day +100 post-ASCT MM response status
Age at Transplant
Response status < 65 years (n=243) ≥ 65 years (n=97) Total
sCR 3 (1%) 0 (0%) 3
CR 22 (9%) 7 (7%) 29
VGPR 117 (48%) 56 (58%) 173
PR 79 (33%) 21 (22%) 100
SD 2 (1%) 2 (2%) 4
PD 5 (2%) 4 (4%) 9
TRM 3 (1%) 0 (0%) 3
Non-secretory / unknown 12 (5%) 7 (7%) 19
Overall response rate (ORR) 221 (91%) 84 (87%) 305
≥VGPR 142 (58%) 63 (65%) 205
sCR/CR 25 (10%) 7 (7%) 32
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TABLE 3
Multivariate analysis of progression-free survival
Variable HR 95% CI Significance
Age (increase of 5y) 0.94 0.86 – 1.03 0.30*
Year of ASCT 0.97 0.91 – 1.03 0.27
Pre-ASCT hemoglobin (increase of 1 g/dL) 0.89 0.83 – 0.96 0.0029
Thalidomide or lenalidomide with induction 1.25 0.91 – 1.72 0.18
Cyclophosphamide mobilization 0.72 0.53 – 0.97 0.030
FISH/cytogenetic high risk 1.47 0.86 – 2.50 0.16
Pre-ASCT response
  PR vs. ≥VGPR 0.48 0.35 – 0.66 <0.0001
  PR vs. <PR 1.22 0.69 – 2.17
*From test of non-inferiority
n=322; 58% events (one subject fewer than OS due to missing data)
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TABLE 4
Multivariate analysis of overall survival
Variable HR 95% CI p-value
Age (increase of 5y) 1.06 0.94 – 1.19 0.025*
Year of ASCT 0.98 0.90 – 1.06 0.56
Pre-ASCT hemoglobin (increase of 1 g/dL) 0.89 0.81 – 0.98 0.019
FISH/cytogenetic high risk 2.92 1.63 – 5.23 0.0003
Pre-ASCT response
  ≥VGPR 0.60 0.39 – 0.92 0.0051
  <PR 1.76 0.89 – 3.50
*From test of non-inferiority
n=323; 35% events
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